Novozymes announces that the Board has appointed two new Executive Vice Presidents for Novozymes' Executive Management, namely Thomas Nagy and Thomas Videbæk. Arne Schmidt will be retiring with effect from October 1 after 37 years with Novo Nordisk and Novozymes. There will also be a number of structural changes in the Executive Management and the organization. Download the full stock exchange announcement
Changes in Novozymes' Executive Management as of October 1, 2007
| Source: Novonesis (Novozymes A/S)
Recommended Reading
-
COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the...
Read More -
Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share...
Read More